CD155 in Bladder Cancer

Predictive Value of CD155 for Survival and Effectiveness of Chemotherapy in Patients With Muscle Invasive Bladder Cancer

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03789682

Enrollment

151

Registered

2018-12-28

Start date

2018-01-01

Completion date

2025-01-01

Last updated

2025-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder Cancer

Brief summary

This research is designed to investigate the prognostic and predictive value of CD155 in muscle invasive bladder cancer.

Interventions

DRUGAdjuvant chemotherapy

adjuvant chemotherapy using Gemcitabine plus Cisplatin

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 85 Years

Healthy volunteers

Inclusion criteria

* patients with non-metastatic muscle invasive bladder cancer * pathology confirmed urothelial carcinoma * underwent cystectomy and pelvic lymph node dissection

Exclusion criteria

* not enough tissue for immunohistochemistry * patients with a second neoplasm

Design outcomes

Primary

Measure	Time frame	Description
Recurrence free survival	2018.1.1-2023.12.31	Time to recurrence or metastasis

Secondary

Measure	Time frame	Description
Overall survival	2018.1.1-2028.1.1	Time to death
Benefit from neoadjuvant chemotherapy	2018.1.1-2028.1.1	response to neoadjuvant chemotherapy
Benefit from adjuvant chemotherapy	2018.1.1-2028.1.1	Survival analysis grouped by adjuvant chemotherapy

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026